Navigation Links
Labopharm provides update on U.S. regulatory process for once-daily Tramadol
Date:9/24/2007

Company Believes Robust Clinical Data Package Provided in NDA Demonstrates

Efficacy and Safety of Once-Daily Tramadol Formulation

LAVAL, QC, Sept. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that is has requested a meeting with the U.S. Food and Drug Administration (FDA), regarding the Company's New Drug Application (NDA) for its once-daily formulation of tramadol. Based on additional analysis that Labopharm has performed, as well as further discussions with its regulatory advisors, the Company believes that it has demonstrated the efficacy and safety of its once-daily tramadol formulation.

Based on data from the Company's global clinical trial program submitted with the NDA, including a positive Phase III study conducted in accordance with a Special Protocol Assessment, Labopharm strongly believes that it has provided the FDA with more than adequate evidence of the efficacy and safety of its once-daily formulation of tramadol.

Should Labopharm and the Agency fail to mutually agree on a path forward toward final regulatory approval, or should the FDA not grant the meeting within the next 30 days, Labopharm plans to appeal the FDA's current decision through the Agency's Formal Dispute Resolution process.

Labopharm's NDA for once-daily tramadol included data from the Company's global clinical development program including six Phase III clinical studies and 12 pharmacokinetic studies. Combined, more than 2400 patients have been exposed to Labopharm's once-daily tramadol in clinical studies.

About the FDA's Formal Dispute Resolution Process

FDA regulations provide a mechanism for those seeking regulatory approval of a drug product through a New Drug Application (NDA) to obtain formal review of any Agency decision through a Formal Dispute Resolution process by raising the matter with the supervisor of the employee who made the decision. If the issue is not resolved at the primary supervisory level, the applicant may request that the matter be reviewed at the next higher supervisory level. This process may continue through the Agency's chain of command, through the Centers to the Commissioner of Food and Drugs. The Formal Dispute Resolution process exists to encourage open, prompt discussion of scientific (including medical) disputes and procedural (including administrative) disputes that arise during the drug development, new drug review, generic drug review, and post-marketing oversight processes.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process for drug approval and the commercialization of the Company's products, if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Protein provides antioxidant protection to Neurons
2. Acupuncture provides relief
3. Micro-camera provides new breast imaging technique
4. Hormone therapy provides no heart benefit
5. MicroRNA provides new insight into birth defects
6. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
7. Neurobiology Provides Answers To Block Memory-Related Drug Cravings
8. Cholesterol provides immunity against infection by certain parasites
9. John Hopkins CGHH program provides Global Health education
10. London Hospital Provides Specialized Care For Pregnant Women
11. Hope Lodges provides free stay to cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance ... their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as ...
(Date:6/27/2017)... ... June 27, 2017 , ... A+ Orthodontics ... dental specialty that focuses on treating alignment and occlusion irregularities. Treatment often includes ... , North Hollywood dentist , Dr. Garemani, along with Dr. Reza ...
(Date:6/26/2017)... ... 26, 2017 , ... Antoine Dental Center is now offering various types of dental ... act as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant ... a sturdy, lasting new root for the tooth. , Several types of dental implants ...
(Date:6/26/2017)... ... June 26, 2017 , ... A ... revolutionizing the way women look and feel about themselves and their sexual encounters. ... sexual dysfunction and urinary leakage head on with a ground breaking medical technique ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing teeth ... or without a referral. Dr. Cotey is a trusted dentist who has placed many ... option. , Patients with missing teeth in Fitchburg, WI, are encouraged to find out ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... , President and CEO, will represent the Company in a ... Healthcare Conference on Tuesday, June 13, 2017 at 10:40 a.m. ... at Terranea Resort in Rancho Palos Verdes, CA. ... for the event will be available on the Company,s website ...
Breaking Medicine Technology: